The use of durable replica moulds with high-feature resolution has been proposed as an inexpensive and convenient route for the manufacture of microstructured materials. A simple and fast duplication method, it involves the use of a master mould to create durable polymer replicas, using polydimethylsiloxane (PDMS). The application of PDMS offers numerous advantages due to its intrinsic properties such as its biocompatibility, affordable price, transparency (240nm-1100nm) as well as its autofluorescence. The replica process enables fast and easy manufacturing since it can be covalently stuck to a glass substrate, using plasma treatment to form sealed microfluidic devices. The replica process is clean and precise, while multiple replications can be obtained from one master. This dramatically decreases both the expenditure and the time required to create specific patterns that need to be used consistently in the creation of various devices.
MicroLIQUID manufactures polymer SU-8 master moulds on silicon wafers, which are widely used to produce microfluidic disposables in the development and prototyping stage. In addition, we generate series of PDMS copies with excellent reproducibility and precision. MicroLIQUID offers high resolution moulds with a standard deviation of under 2%. microLIQUID is working in applications such as droplet generation for PCR diagnostics, single-cell analysis and high throughput screening among others. The moulds are highly reusable since we offer several treatments to increase the service life of the mould. This replica method will help you choose the optimum design for your product prior to scaling up to mass production. Indeed, more than 50 companies all over the world have already done so.
The company is now celebrating a decade working on the design and manufacture of novel microfluidic products for our customers; we are proud and delighted to have made it this far, and excited about the future!
During this time, we´ve grown in many ways, for example by increasing the number of employees and clients, as well as boosting revenues. We have collaborated successfully in more than 300 microfluidic projects around the world, doubling our turnover since 2014 and we have gained vast experience in this business dimension. In addition, we develop new value propositions to our customers, offering unique complete value chain solutions from complex microfluidic consumables that can be processed on our own design automated instrumentation (e.g. Point of Care instruments).
Since its establishment, microLIQUID has focused on delivering quality to its customers and fulfilling their expectations. This is the reason why so many of our clients and partners trust our professionalism and appreciate the individual approach we provide.
We are grateful to all those who have worked with us and have helped us over these last 10 years to develop our company. microLIQUID´s success would not have come to fruition had it not been for their unwavering support.
We are optimistic about what lies ahead and are very confident that we will be able to help many more future customers around the world to manufacture solutions based on our microfluidics and automated instrument solutions in fields such as rapid testing, immuno-oncology, NGS and Precision medicine, liquid biopsy and drug delivery among others.
MicroLIQUID has shown once again that it strives to develop new point-of-care platforms by using the latest technologies in microfluidics.
In this project, microLIQUID will be working together with European leaders, both from academia and industry, to develop new PoC applications.
We invite you to read the press release issued by Ghent University at the start of the project in October 2017.
“Ghent, Belgium – October 1, 2017 – Ghent University and its project partners today announced the launch of the PoCOsteo project. Together they will develop and validate a point-of-care in-office device for identifying individuals at high risk of osteoporosis and osteoporotic fracture. The project is supported by the European Union’s Horizon 2020 Framework Programme for Industrial leadership in nanotechnologies, advanced materials, biotechnology and advanced manufacturing and processing (H2020-NMBP). The overall goal of the project is the development, clinical validation and preparation for commercialisation of a point-of-care tool for bone disease (a.o. osteoporosis) prevention, detection and treatment.
Indeed, as a consequence of the ageing of the society, osteoporosis (literally “porous bone”) and its complications is becoming more and more prevalent, making the bone disease a health priority in many parts of the world. Usually osteoporosis manifests itself in a drastic manner, i.e. through fracture of the osteoporotic bone in the affected individual. This causes a serious burden for the patient and a high medical care cost for the society. Currently osteoporosis is commonly known as a “silent killer” disease. Up to 20% of patients die in the first year following a hip fracture, mostly due to pre-existing medical conditions. Less than half of those who survive the hip fracture regain their previous level of function1. Early detection of individuals at risk of osteoporosis and starting a suitable treatment before fractures and complications arise would drastically improve the current situation. Until now little or no measures for prevention or early detection of osteoporosis are taken, because no simple, yet sufficiently accurate or sensitive tools for early detection are available.
The PoCOsteo system will employ electrochemical detection and brings together proteomics, genomics and microfluidics technologies. The in-office test will provide the results in real-time during consultation and can be performed by unskilled technicians even at rural areas where access to current state-of-the-art equipment is limited. The design will limit the amount of both expensive reagents and blood samples needed for the tests and so it not only reduces the cost of each test, which is of great importance, especially nowadays when full reimbursement is not practiced in many countries, but also reduces the patient’s pain and discomfort.
The project will be supported and advised by the IOF, the International Osteoporosis Foundation, which is the main global alliance of patient societies, research organizations, healthcare professionals and international companies working to promote bone, muscle and joint health.
Over the next four years, PoCOsteo will be coordinated by Ghent University. Industrial, academic and clinical partners will bring their expertise to the project: Universitat Rovira I Virgili and microLIQUID (Spain), Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung (Germany), Labman Automation (United Kingdom), Medizinische Universität Graz (Austria), Endocrinology and Metabolism Research Institute (Iran) and Fundico (Belgium).”
In microfluidics, sharing is hard. However, practitioners are exploring new ways to share designs and devices along with their experience. Many thanks to Vivien Marx and Nature for giving microLIQUID the opportunity to describe our experience in Volume 15, Number 3 of the magazine NATURE.
Some of the key aspects of microLIQUID´s origins are set out in this review, as well as a description of our business model, which aims to manufacture new robust products and introduce them into the market.
Nature explains that microLIQUID was spun out of the technology centre IKERLAN in 2008. In microLIQUID´s first years, the customers were mainly academics requesting microfluidic chip development. Today, around 15% of microLIQUID customers are academics and R&D centres working with state-of-the-art technologies, and the rest are pharmaceutical and biotech companies, of which around 55% are in Europe and around 40% are in the U.S.. The review also points out that working with academics is essential for the future of the field because of the way it drives us toward next-generation solutions.
In 2013, the company switched from making stand-alone chips to designing and manufacturing microfluidic chips and automated instruments. This new value proposition reflects customer needs. It plays out well because it´s hard to launch a microfluidic device without knowing the automated instrumentation it will be associated with. This helps to explain why many microfluidic chips do not make it to market even after many years in development.
microLIQUID will be at Analytica 2018 this April 09-13 in München, Germany.
On behalf of our company, if you are attending to the event, we want to take advantage to have a meeting with you in order to talk about our common interests.
We will be pleased to invite you to join us at our stand A3.220, where we will be showcasing our latest offerings and technologies, and we will have our top product experts on hand to answer your questions.
Looking forward to seeing you.
microLIQUID is pleased to announce that we will be exhibiting at several international events during this year. See some of them below:
We will be demonstrating our latest offerings and technologies and we will have our top product experts on hand to answer your questions. Therefore, don´t hesitate to send us an e-mail to [email protected] if you are interested in scheduling a meeting with one of our experts on site.
We would like to thank you for devoting some of your time in visiting our booth at Compamed, held in Düsseldorf, DE, from the 13th to the 16th of November of 2017. We hope that you had a good time and enjoyed your visit to the city.
It was our pleasure and honor, and we enjoyed many inspiring conversations. Moreover, we were impressed by the number of visitors and the great interest in our products.
In case we weren’t able to answer some of your questions about our products and services while you were there, we encourage you to contact us at the following email adress: [email protected]
We look forward to being able to be of service to you.
microLIQUID will be at Compamed 2017 this November 13-16 in Düseldorf, Germany.
We will be pleased to invite you to join Hall 8a/F34.1, where we will be demonstrating our latest offerings and technologies (services in mass manufacturing of microfluidic components and automated instruments for the IVD and pharma sector, for example.) and we will have our top product experts on hand to answer your questions.
Looking forward to seeing you.